Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- GLs on Proper Use of Antibacterials Completed
May 14, 2001
- Eisai Ties Up with Neurogenetics
May 14, 2001
- OTC NEWS IN BRIEF
May 14, 2001
- BUSINESS NEWS IN BRIEF -1-
May 14, 2001
- Sumitomo Corp. Establishes Bioventure Investment Fund
May 14, 2001
- DIAGNOSTIC NEWS IN BRIEF
May 14, 2001
- Rohto to Launch Obagi Series of Skin Care Products in Japan
May 14, 2001
- MEDICAL DEVICE NEWS IN BRIEF
May 14, 2001
- WORLD NEWS IN BREF
May 14, 2001
- Japan-EU Mutual GMP Recognition Accord to Be Approved by Diet
May 14, 2001
- 6 New Drugs Including Insulin-lyspro Approved
May 14, 2001
- Chugai Starts V's 21 Plan: President Nagayama
May 14, 2001
- PMSB Proposes NDA Dossier Guide According to CTD
May 14, 2001
- Yamanouchi to Boost Sales to\600 Bil. in FY2005: President Takenaka
May 14, 2001
- REGULATORY NEWS IN BRIEF -1-
May 14, 2001
- Hitachi to Develop New Clinical Data Management System with AstraZeneca
May 14, 2001
- REGULATORY NEWS IN BRIEF -2-
May 14, 2001
- FTC Inspects Tohoku Wholesalers on Suspicion of Price Cartel
May 14, 2001
- Kenporen Predicts 6.6% Increase in Medical Costs for Elderly
May 14, 2001
- JPMA to Prepare for ICH6 in Japan in 2003
May 14, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…